What comes to your mind when you think about breast cancer? It would most probably be ‘chemotherapy,’ ‘fear of a long process of treatment,’ ‘high costs,’ the fear of cancer coming back, and so on. These thoughts can be controlled with the right knowledge and right breast cancer treatments.
Researchers and oncologists have made new and promising forms of treatment for breast cancer. It’s time to personalize your treatment!
Our test classiﬁes patients as ‘low-risk’ or ‘high-risk’ based on the patient’s breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.
Plan the ideal treatment
CanAssist Breast is a test that helps to plan the ideal treatment by predicting the breast cancer recurrence risk within five years of surgery. The risk of recurrence is lesser in early-stage breast cancer (Stage 1 and Stage 2), and hence, it is important for doctors and the patients to plan out a suitable course of treatment based on the breast cancer recurrence risk score.
Until a few years back, oncologists and clinicians were deciding cancer treatments based on age, tumor size, node status, grade, ER, PR and HER2 status. OncoStem realized there was a gap in the decision-making paradigm and understanding the tumor biology to comprehend the cancer progression and its aggressiveness would significantly change treatments depending on an individual’s tumor biology.
Tests similar to CanAssist Breast have been based on genomic analysis, whereas CanAssist Breast involves proteomics analysis. The genomics method considers genes of interest in the genome of a cell, whereas CanAssist Breast’s proteomics technique studies the proteins of interest produced by the cell. A 5-year study by OncoStem Diagnostics, recently published online, explains the detailed analysis and results that lead to the test, CanAssist Breast.
Your tumor is different, just like you are, as an individual.
Doctors and oncologists have to know as much possible about your tumor for optimal and ideal treatment.
A way forward – scientific, machine-learning precision
Artificial intelligence and machine learning is an emerging approach in the healthcare sector including the treatment of breast cancer. CanAssist Breast is the first such test developed in India, specifically for Indian patients. It determines the tumor’s biochemical fingerprint and assesses its aggressiveness. Assessing the tumor biology in detail, the test considers five key biomarkers that are involved in recurrence-related pathways in the cell. Based on this combined analysis performed by proteomics-based technology, the information is then assessed by a statistical algorithm that provides a score between 0 and 100 – whether the patient is at low-risk or high-risk for cancer recurrence. A ‘CAB risk score’ less than 15.5 indicates a low-risk. Depending on each patient’s unique CAB risk score, the doctors can thus plan an ideal treatment tailored to an individual’s patient.
A decision that doctors and patients must make:
‘Fear’ is the most shared and challenging emotion that cancer brings with it. However, fearful a patient might be; it is essential for the patients to know and consider that their treatment can be different from that of the other patients.
Knowing who is eligible for the CanAssist-Breast test can help both patients and doctors.
The patients must meet the below criteria to take CanAssist Breast:
- Patients with early-stage, invasive breast cancer
- Patients with hormone receptor-positive (“ER+ and/or PR+”) and HER2- negative disease
- Lymph node-negative or up to 3 lymph node-positive
- Patients should not have gone through neo-adjuvant chemotherapy
In India alone, 150,000 women are diagnosed with breast cancer every year. Of these, around 50 percent fall in the early-stage breast cancer category and a majority of them are eligible for this test.
Take your decision together
If you or someone among your friends or family are going through breast cancer (early-stage), you must consider taking CanAssist Breast before starting the treatment. If you are an oncologist or a doctor, maybe your patients could avoid the unnecessary treatments and the side effects most usually associated with chemotherapy.
Doctors must suggest the test to their eligible patients and patients must ask their doctors about the test score and personalize their treatment accordingly.
Want to know more about CanAssist Breast? Get in touch with us.
Are you amongst the millions who associate breast cancer with fatality; a disease that is almost impossible to cure and one that definitely involves chemotherapy? Most people believe that cancer treatments and medicines have little benefit. However, a look into new findings and discoveries in the field of oncology is enough to change this common perception about breast cancer.
For years, doctors and oncologists have chosen chemotherapy and radiation as a post-surgical breast cancer treatment. The knowledge, willingness, and proactive approach of the oncologists’ and their involvement with the patient’s treatment play a vital role in breast cancer treatment.
The oncologist and the patient
The oncologist is not only responsible for the diagnosis but is also responsible for providing clarity and knowledge to the patient about their cancer. Most importantly, the oncologist is responsible for deciding and charting out the best treatment course for the patient. Discussions surrounding prognosis often require oncologists to be sensitive, honest, and encouraging.
The treatment to a particular breast cancer patient and the response to treatment is unique to each patient, and the oncologist must share relevant information with the patient. Apart from this, the oncologists are responsible for post-treatment follow-up to assess the effectiveness of the treatment.
Oncologists have to consider many factors when determining a patient’s treatment and one thing that is often difficult to decide is whether a patient should be given chemotherapy or not. Several factors are considered:
- The size of the breast cancer tumor
- The stage of breast cancer
- Whether cancer is only in the breast or has spread to other parts of the body
- The hormone-receptor status of the cancer
- Whether the cancer is triple-negative (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative)
- The rate of cell growth
- If the cancer is likely to come back (recurrence)
- Factors such as the age, menopausal status, and general health of the patient.
According to an assessment by WHO, cancer cases in India will multiply over five times by 2025.
Most patients associate cancer with chemotherapy and one of their first set of questions include queries about chemotherapy: How many sessions of chemotherapy will be required, what are the side-effects, what are the costs involved, will chemotherapy benefit, and what exactly happens during chemotherapy? Among other common questions are: will cancer come back after the surgery? How aggressive is cancer and how fast is it spreading?
A large number of patients and their families aren’t aware of the alternative treatments for breast cancer that are available in the country today. Hence, it is the oncologist’s responsibility to introduce the patients to new treatment options so that the patients consider all the available options.
Oncologists and cancer clinics have to be updated with the latest research and findings in the field of medical research to be able to provide the best treatment to their patients.
Breast cancer trends and cure
In India, breast cancer cases are on the rise. There has been an increase in the number of discoveries, alternative cancer care options, and innovative personalized treatment options for breast cancer patients in India.
In the last five decades, breast cancer treatment has become the model for the development and success of tailored medical treatment.
Therapeutic approaches for breast cancer have changed over the past few decades, and the use of systemic therapy for early and advanced disease tailored to the individual patient holds the promise of delivering treatment to those in need and who could benefit the most. While we’re nowhere near where we should be or could be—in either preventing or treating cancer—science has led to evident progress in treating breast cancers of different kinds.
Advances in hormone therapy for hormone receptor-positive cancer
Some breast cancers are driven by natural hormones, estrogen and progesterone. These are referred to as hormone receptor-positive if they are estrogen receptor-positive (ER positive) and/or progesterone receptor-positive (PR positive). Hormone therapy for breast cancer is only used to treat cancers that are ER or PR positive.
Despite conventional hormone therapy, approximately 20–30% of patients with hormone receptor-positive breast cancer suffer recurrences and the development of metastatic disease as they experience a biochemical mechanism of resistance. Considerable progress has been made in this area, and newer therapeutic targets have been developed against a number of hormonal resistance mechanisms.
Are all patients with early breast cancer benefiting from chemotherapy? A number of experts and oncologists asked this question. Some delved deeper into it. With this question in mind, global investigators motivated by the development of new prognostic and predictive tests such as OncoStem’s CanAssist Breast. The test focuses on personalizing breast cancer treatment to avoid over treatment and under treatment.
Clinical research is currently evaluating new therapeutic approaches and is identifying specific biological subsets that could determine a patient’s ability to respond to a particular treatment.
Scientific, machine-learning precision – CanAssist Breast
Artificial intelligence and machine learning is an emerging approach to breast cancer. CanAssist Breast is the first such test developed in India, specifically for Indian patients. It determines the tumor’s fingerprint and assesses its aggressiveness. Assessing the tumor biology in detail, the test considers key biomarkers. Based on this combined analysis performed by proteomics based technology, the information is then assessed by a statistical algorithm that provides a score – whether the patient is at low or high risk for breast cancer recurrence.
The importance of medical research
The advent of new drugs targeting specific actionable targets has led to considerable progress in the treatment of breast cancer over the past few years. Yet, some challenges such as resistance to systemic therapy, the high cost of treatments, and limited availability in many parts of the country still remain.
Experts continue to find ways to improve the available technology to provide proper guidance for those living with breast cancer and for those at high risk of developing it.
The author of this blog, Dr.Jayanti Thumsi, has been a practicing breast oncologist for 16 years, has performed 3500 breast surgeries, and 2500 other surgeries. She is an expert in Breast conservation and Breast Reconstruction surgeries. With a keen interest in spreading breast cancer awareness among women, she has conducted 258 awareness programs and has educated 158000 women. She is also the founder trustee of the CREST Foundation working to decrease the burden of breast cancer. Her book, Lump to Laughter, highlights the emotional journey of women going through breast cancer treatment.